Vera Therapeutics Q1 net loss widens

Vera Therapeutics, Inc. Class A

VERA

0.00

Overview

U.S. biotech firm's Q1 net loss widened
Operating expenses more than doubled yr/yr as company prepares for potential drug launch

Result Drivers

PRE-COMMERCIAL SPENDING - Operating expenses rose sharply due to investments in sales, marketing, market access, compliance, and commercial operations ahead of potential atacicept launch

Company press release: ID:nGNX2fp8Qp

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income	Miss	-$121.03 mln	-$89.89 mln (8 Analysts)
Q1 Operating Income	Miss	-$125.13 mln	-$92.74 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vera Therapeutics, Inc is $78.00, about 113.1% above its May 6 closing price of $36.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.